News

Candel Therapeutics announced that it has acquired all oncolytic and other Herpes Simplex Virus (HSV) based assets from PeriphaGen, Inc., bringing its vector engineering, production…
Read More...

Galecto, the leading developer of galectin modulators for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and cancer, and PharmAkea, Inc., a privately…
Read More...

Curis, Inc. announced that it has entered into an option and license agreement to acquire exclusive, worldwide rights from ImmuNext Inc. (ImmuNext) to develop and commercialize…
Read More...

AstraZeneca announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dapagliflozin) to reduce…
Read More...

Merck, known as MSD outside the United States and Canada, announced an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical Co, Ltd., (“Taiho”) and…
Read More...

Bicycle Therapeutics plc announced a second collaboration with Cancer Research UK in which Cancer Research UK will fund and sponsor development of BT7401, a multivalent Bicycle CD137…
Read More...

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the initiation of a research collaboration with AstraZeneca to evaluate small activating RNA ("saRNA")…
Read More...

Veristat, a full-service CRO, announced that it has completed the acquisition of The Clinical Trial Company Ltd. (TCTC Group), a global Contract Research Organization headquartered in…
Read More...

InxMed (Shanghai) Co., Ltd., a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced that the company has…
Read More...

ATAI Life Sciences AG announced that it has partnered with Neuronasal Inc., to develop a short-term treatment for mild Traumatic Brain Injury (mTBI) or concussion. Neuronasal's…
Read More...

Pulmatrix, Inc. a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced that it has entered into a research…
Read More...

Abcam plc, a global innovator in life science reagents and tools, is pleased to announce the successful completion of the acquisition of Expedeon's Proteomics and Immunology business,…
Read More...

Charles River Laboratories International announced that it has completed the previously announced acquisition of HemaCare Corporation for approximately $380 million in cash, or $25.40…
Read More...

Leap Therapeutics and BeiGene announced an exclusive option and license agreement for the clinical development and commercialization of DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody,…
Read More...

AstraZeneca announced that it has agreed to sell the commercial rights to Arimidex (anastrozole) and Casodex (bicalutamide) in a number of European, African and other countries1 to…
Read More...

PharmaMar and Jazz Pharmaceuticals plc announced that PharmaMar and Jazz Pharmaceuticals Ireland Limited have entered into an exclusive license agreement for lurbinectedin in the United…
Read More...

Genmab A/S and CureVac AG announced that Genmab and CureVac have entered into a research collaboration and license agreement. This strategic partnership will focus on the research and…
Read More...

Achillion Pharmaceuticals announced that its shareholders have approved the acquisition of Achillion by Alexion Pharmaceuticals. Achillion continues to expect the transaction to close…
Read More...

Dicerna Pharmaceuticals, Inc. announced the successful closing of the research collaboration and licensing agreement between Dicerna and Roche following expiration of the waiting period…
Read More...

BC Platforms announced that it has closed a USD $15 million financing round alongside a new commercial collaboration with IQVIA. The round was led by IQVIA in conjunction with…
Read More...